Luna Innovations Incorporated (Nasdaq: LUNA) 45.4% HIGHER; announced a multi-year agreement that amends its development and supply agreement with Intuitive Surgical, Inc., (Nasdaq: ISRG). The agreement provides for the achievement of various development milestones through 2015.
China Recycling Energy Corporation (Nasdaq: CREG) 21.5% HIGHER; China Recycling surging back above $1.50 today on volume. Shares hit a 52-week high at $1.75. Market indicators hint that the stock is overbought.
Response Genetics, Inc. (Nasdaq: RGDX) 15.2% HIGHER; announced that it has recently executed a provider contract with Blue Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has 7.4 million members, most of whom are located in the State of Illinois.
Mandalay Digital Group (Nasdaq: MNDL) 13.8% LOWER; continuing lower after it filed $30 million common stock shelf last week.
National Bank of Greece (NYSE: NBG) 13.3% HIGHER; Higher on news that Greece met requirements for another round of funding.
Guanwei Recycling Corp. (Nasdaq: GPRC) 13.1% HIGHER; another China recycling name up today. Volume here is over 100,000 shares, versus its typical trading volume of 38,000 shares.
Natus Medical, Inc. (Nasdaq: BABY) 12.6% LOWER; sees revenue for the second quarter of 2013 is expected to be between $81 million and $82 million versus previous guidance of $86 million to $90 million. The Wall Street consensus is $88.6 million.
Linn Energy (Nasdaq: LINE) 11.5% HIGHER; higher today as BofA/Merrill Lynch upgraded its rating on the company from Neutral to Buy.
ClickSoftware Technologies Ltd. (Nasdaq: CKSW) 9.9% LOWER; announced that it anticipates revenues for the second quarter ended June 30, 2013 to be approximately $24.5 million, representing about 9% growth year over year. The company also sees a loss of $0.06 to $0.08 per share, with the Street expecting EPS of $0.03.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) 8.6% LOWER; that the first patient has been enrolled in a Phase 2a trial of ORMD-0801, an orally ingestible insulin capsule, on patients with type 2 diabetes. The current trial is to be a randomized, double-blind study designed to assess the safety of ORMD-0801.
Noodles & Company (Nasdaq: NDLS) 7.2% LOWER; pulling back following its recent IPO and surge higher as Wedbush issued cautious commentary on the name, initiating coverage with a Neutral rating.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW *NEW – Download StreetInsider’s FREE iPhone and iPad App – Click Here begin ad tag (tile=12) — End ad tag —